Search

News Post hoc Analysis of the FRAME Study –⁠ Romosozumab in the Treatment of Osteoporosis in the European Population

An interesting finding from the FRAME study, which evaluated the treatment of postmenopausal women with osteoporosis using romosozumab, was the significant differences in fracture incidence among patients from various geographic regions. The following post hoc analysis specifically focused on data from European women.

Source: Osteoporosis – Trends in Sequential Therapy 14. 11. 2023

News Efficacy of Lorlatinib in Patients with ROS1-Positive NSCLC in Clinical Practice

Interesting real-world data have been brought by a study on the efficacy of lorlatinib in patients with non-small cell lung cancer (NSCLC) with a mutation in the ROS1 gene.

Source: Genetic Profile and Treatment of NSCLC 20. 4. 2022

News How Do Vaccinated MS Patients Fare with COVID-19 Antibodies?

Which disease-modifying drugs for the treatment of multiple sclerosis (MS) reduce the humoral response to COVID-19 vaccination? And does the quantity of post-vaccination antibodies vary depending on the specific vaccine?

Source: Multiple Sclerosis 21. 12. 2021

News Itoprid helps diabetics with reduced gastrointestinal motility improve diabetes control

The prokinetic itoprid led not only to the alleviation of gastroparesis symptoms and an improvement in quality of life in a prospective multicenter observational study on patients with diabetes and reduced gastrointestinal (GI) motility, but also to an improvement in glycemic parameters.

Source: Gastrointestinal Treatment 21. 4. 2020

News Meta-analysis of the Effectiveness of Romosozumab in the Treatment of Postmenopausal Osteoporosis

Osteoporosis is a prevalent disease with unmet therapeutic needs. Whether the anti-sclerostin antibody romosozumab can offer an effective improvement in osteoporosis treatment outcomes in postmenopausal women was the central question addressed by the meta-analysis presented below.

Source: Osteoporosis – Trends in Sequential Therapy 29. 2. 2024

News Evaluation of Various VWF Concentrates Regarding Their Ability to Mediate Platelet Binding to Collagen

The study by London researchers on various VWF concentrates focused, among other things, on evaluating their ability to mediate platelet binding to collagen.

Source: Von Willebrand Disease 27. 8. 2020

News Correct Selection of Appropriate Incontinence Aid is Crucial for Addressing Patient's Difficulties

Urinary incontinence is an uncomfortable issue that can be resolved by choosing the right incontinence aids. Selecting a quality product is most important for the patient −⁠ it affects their comfort and mental well-being, but choosing the right aid can also be complicated for doctors. The market offers many products of different brands and qualities, where the absorption capacity is often the main selection criteria. However, other important aspects must also be considered.

Source: Incontinence 12. 5. 2022

News According to which parameters can we best assess the quality of incontinence aids?

Properly chosen incontinence aid significantly influences the user's quality of life. When selecting incontinence aids, it is very important to consider their individual properties and parameters. While in European countries the absorbency of the aid is mainly assessed alongside the product's size and the user's gender, other parameters are evaluated elsewhere in the world. So what should we primarily focus on when choosing an aid?

Source: Incontinence 12. 5. 2022

News Current Results of Brigatinib in the Treatment of Lung Cancer

The results of the primary analysis showed a significant extension of PFS in patients with non-small cell lung cancer (NSCLC) treated with brigatinib compared to crizotinib. The recently published secondary analysis confirms these results.

Source: Non-Small Cell Lung Cancer 4. 6. 2021

News Fatigue in Multiple Sclerosis: What Can Teriflunomide Do?

An article by French authors published in January this year in the journal Multiple Sclerosis and Related Disorders evaluated the effect of teriflunomide on fatigue in patients with multiple sclerosis in real-world practice.

Source: Multiple Sclerosis 19. 4. 2021

News New drugs in CLL may also carry specific risks of adverse effects. How to minimize and manage them?

The possibilities for the treatment of chronic lymphocytic leukemia (CLL) have greatly expanded in recent years. Significant changes have been brought particularly by small molecule-based therapeutic agents (inhibitors), which have shown significant efficacy in both previously untreated patients and those who have relapsed from CLL. When choosing the best treatment strategy for patients with CLL, it is of course necessary to consider the specific adverse effects of both new and previously used drugs, the overall condition of the patient, comorbidities, and the so-called individual risk of serious side effects of the drugs.

Source: Chronic Lymphocytic Leukemia 13. 3. 2020

News MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information

How to offer a helping hand to patients amidst the flood of information and why is communication perhaps more important than ever? And what should the standards in the doctor-patient relationship with multiple sclerosis be? This unusual topic was explored in a publication in the journal Neurosciences.

Source: Multiple Sclerosis 15. 8. 2023

News Chairwoman of Revma Liga ČR: I Hope We Improve Our Approach and Treatment of Osteoporosis in the Czech Republic

Patients with inflammatory rheumatic diseases have a significantly increased risk of developing osteoporosis and related fractures. At the same time, this disease is considerably underestimated in the Czech Republic, and more attention is given to it only at the stage of osteoporotic fractures. To what extent does the patient organization Revma Liga ČR, which unites patients with rheumatic diseases, engage in this issue? We asked its chairwoman Edita Müllerová.

Source: Osteoporosis – Trends in Sequential Therapy 20. 12. 2023

News Safety and Effectiveness of Lurasidone in Adolescents with Schizophrenia

An open-label extension of a placebo-controlled study involving 271 patients aged 13–17 years with schizophrenia showed minimal impact on body weight, lipid levels, prolactin, and blood glucose during 2 years of treatment while maintaining and deepening the alleviation of schizophrenia symptoms.

Source: Modern Treatment of Schizophrenia 18. 5. 2021

News Targeted Therapy for DLBCL Patients Who Cannot Undergo Bone Marrow Transplant

An international team of hemato-oncologists has been involved in testing polatuzumab vedotin in patients with diffuse large B-cell lymphoma (DLBCL) who have an unfavorable prognosis. In an article published at the beginning of 2020 in the Journal of Clinical Oncology, they analyze data collected in the early phases of clinical evaluation.

Source: Non-Hodgkin Lymphomas and CLL 11. 5. 2020